Successful translational R&D needs equity ownership

12/6/2012 | Forbes

Early-stage translational research and development projects in life sciences are likely to fall flat in the absence of equity ownership in startup companies, writes Atlas Venture partner Bruce Booth. Equity ownership "rewards the successful entrepreneur and binds them together with the academic founders, key advisors, and the broader shareholders," he writes. Equity rewards risk-takers and entrepreneurs, thus encouraging investment, he writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN